Korea Biochem Pharm has passed the actual inspection of TEVA on component manufacturing facilities
Korea Biochem Pharm, a branch of Korea United Pharm (president Duk-young Kang), has passed an actual inspection of TEVA on manufacturing facilities.
As making a contract with an Israel global pharmaceutical company, TEVA,to sell its first self-developed drug ‘Clanza CR Tab’in Russia and Eastern ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
